Investigation of semaglutide aimed to build on the encouraging early signs noted within the LEAN trial of liraglutide - another GLP-1 agonist (see below).44 A 72-week, double-blind, placebo-controlled, phase II trial with biopsy-confirmed NASH was undertaken by Newsome et al.45 Within the trial cohort were histological grades F1–F3, with those randomized to treatment receiving 0.1, 0.2 or 0.4 mg of subcutaneous semaglutide or placebo. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.